

Life Sciences

Lathrop GPM represents clients in the Life Sciences industry in all areas of intellectual property representation, including IP portfolio building, prosecution, due diligence, transactions, and litigation.

Extraordinary developments in the field of bioscience are transforming our lives in ways nobody could have anticipated even a short time ago. At the same time, those breakthroughs are creating complex new business, ethical, and legal challenges. Lathrop GPM represents clients in the biotechnology and life sciences sector ranging from large pharmaceutical companies to small start-ups and venture capital groups. We have nearly 70 attorneys, patent agents and technical specialists who have focused expertise in biotechnology, chemistry, high technology, patent litigation and licensing.

Lathrop GPM has a nationwide presence, with offices from Boston to Los Angeles. In keeping with the firm's focus on the intellectual property arena, nearly all of those offices - including Boston, Kansas City, Los Angeles, and Minneapolis - have significant IP practices. Our attorneys are supported by a team of dedicated paralegals that manages and administers the myriad deadlines and technical requirements of patent and trademark offices in the United States and abroad.

In addition to IP needs, bioscience companies seek our advice and counsel in:

- Business strategy for entering the U.S. market
 - Entity formation
 - Capitalization
 - Licensing
- Joint ventures and strategic collaborations
- Contracts and corporate governance

- Distribution
- Design, engineering & manufacturing agreements
- Financing
 - IPO
 - Private offerings
 - Venture capital
- Government regulations and relations
 - Compliance & investigations
- Mergers & acquisitions
- International law
- Human resources
 - Employment contracts
 - Hiring
 - Employment policies
 - Investigations
 - Management training
- Tax treaty
- Real estate
- Recalls and product liability
- Research, development, and licensing agreements

Industry Experience

- Antibodies, CAR-T and immunotherapies
- Biologics
- Biomarkers and diagnostics
- FDA label developments
- Gene therapy
- Implantable and external medical devices
- Novel chemical entities
- Oligonucleotide therapeutics including RNAi/siRNA/miRNA and anti-sense
- Peptide therapeutics/chemistry
- Prodrugs

- Small molecule pharmaceuticals

Additional Highlights

- Assist three of the top 10 global pharmaceutical companies with building out comprehensive and global patent estates in connection with multiple biologics and small molecule products in several therapeutic disease areas, including oncology, immunology, neurology and cardiology.
- Conduct freedom-to-operate (FTO) analyses, IP landscape reviews, and clearance work in connection with both early- and late-stage pharmaceutical products.
- Provide ongoing client counseling and portfolio management in connection with several marketed antibody biologics and small molecules.
- Serve as patent counsel for startup, emerging and mature biotechnology companies across the U.S. and Europe in connection with a variety of platform technologies and product pipelines in areas as diverse as antibody engineering, genome engineering, nucleic acid therapeutics, gene therapy (AAV, Adenovirus), and small molecule advancements.